Shareholder Update & Roadmap for MyMedicalRecords Patent Portfolio

LOS ANGELES, CA--(Marketwired - Dec 24, 2014) - MMRGlobal, Inc. (OTCQB: MMRF), through its wholly owned subsidiary, MyMedicalRecords, Inc. (collectively, "MMR"), today announced that the U.S. District Court for the Central District of California issued an order in response to a motion for judgment on the pleadings agreeing that claims 8-12 of U.S. Patent No. 8,301,466 ("the '466 patent") were directed towards an abstract idea and therefore not directed towards patent eligible subject matter. The '466 patent contains 15 claims, 10 of which are not affected by the Order. The ruling also does not affect other portions of MMR's health information technology patent portfolio which, dating back to filings in 2005, currently includes 13 U.S. patents (with over 300 issued claims), 18 additional pending U.S. patent applications (with over 300 claims), nine foreign patents, including two in Australia, two in Mexico, with others in New Zealand, Singapore, Japan, South Korea, and Canada, and 25 other pending patent applications in foreign countries. The Court's Order does not affect these other patents.

MyMedicalRecords, Inc. will continue to pursue opportunities to monetize its 13 U.S. patents with more than 300 existing claims where appropriate in the burgeoning health information technology marketplace. In the meantime, MMR continues to offer its products and services to enter into license agreements with healthcare professionals including pharmacy chain retailers.

MyMedicalRecords, Inc. also received an order regarding a portion of a September 3, 2014 Claim Construction ruling which construed the term "means for scheduling prescription refills" found in three claims of its 8,498,883 patent ("the '883 patent") to be indefinite. There are a total of 28 claims in the '883 patent, a number of which MMR believes are not affected by the Court's Order. The Company and its patent attorneys remain confident in their positions as to all of MMR's claims, and plans on appealing the Court's decisions to address the validity of the patents at the appellate level sooner than later.

About MMRGlobal, Inc.
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com. View demos and video tutorials of the Company's products and services at www.mmrtheater.com.

Forward-Looking Statements
All statements in this release that are not strictly historical facts are "forward-looking statements." Such forward-looking statements are based on MMR's current assumptions, beliefs and expectations, and involve risks, uncertainties and other factors that may cause MMR's actual results to be materially different from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words such as "expect," "plan," "possibility," "offer," "if," "negotiate," "when," "believe," "will," "estimate," "continue," and similar expressions. Risks, uncertainties, and other factors that could cause or contribute to such differences include, but are not limited to: ongoing and future intellectual property enforcement actions; the ability to successfully litigate or settle claims of patent infringement; MMR's ability to develop, license and monetize its patent and the additional patents in the portfolio for both MMR's health IT and biotechnology IP assets; reliance upon the successful operations of its business partners in selling MMR's products and services, the timing of milestone payments in connection with licensing its IP; MMR's ability to obtain necessary financing, generate sufficient cash flow, and maintain appropriate indebtedness; and the increasing development of market competition in the area of personal and electronic health records. These factors and others are described in more detail in MMR's public filings with the Securities and Exchange Commission, including the risks discussed in the "Risk Factors" section in MMR's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Copies of these reports can be found on MMR's website (www.mmrglobal.com) under the heading "Investor Relations." MMR is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.